181 related articles for article (PubMed ID: 38490767)
1. The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia.
Behrens YL; Pietzsch S; Antić Ž; Zhang Y; Bergmann AK
Best Pract Res Clin Haematol; 2024 Mar; 37(1):101539. PubMed ID: 38490767
[TBL] [Abstract][Full Text] [Related]
2. The Interpretation of Sequence Variants in Myeloid Neoplasms.
Hanbazazh M; Harada S; Reddy V; Mackinnon AC; Harbi D; Morlote D
Am J Clin Pathol; 2021 Oct; 156(5):728-748. PubMed ID: 34155503
[TBL] [Abstract][Full Text] [Related]
3. Implication of cytogenetic and molecular cytogenetic analysis in diagnosis of hematological malignancies in the era of the new sequencing techniques.
Zemanová Z; Michalová K; Březinová J
Cas Lek Cesk; 2019; 158(1):22-27. PubMed ID: 31046388
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology.
Hussaini M
Cancer Control; 2015 Apr; 22(2):158-66. PubMed ID: 26068760
[TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnosis of Hematopoietic Neoplasms: 2018 Update.
Ramchandren R; Jazaerly T; Bluth MH; Gabali AM
Clin Lab Med; 2018 Jun; 38(2):293-310. PubMed ID: 29776632
[TBL] [Abstract][Full Text] [Related]
6. Applications of next-generation sequencing in hematologic malignancies.
Ramkissoon LA; Montgomery ND
Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
[TBL] [Abstract][Full Text] [Related]
7. Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies.
Kim H; Yun JW; Lee ST; Kim HJ; Kim SH; Kim JW;
Ann Lab Med; 2019 Nov; 39(6):515-523. PubMed ID: 31240878
[TBL] [Abstract][Full Text] [Related]
8. Applications of Fluorescence In Situ Hybridization Technology in Malignancies.
Tansatit M
Methods Mol Biol; 2017; 1541():75-90. PubMed ID: 27910016
[TBL] [Abstract][Full Text] [Related]
9. Overview. Cytogenetic analysis in haematology.
Bain BJ
Best Pract Res Clin Haematol; 2001 Sep; 14(3):463-77. PubMed ID: 11640865
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics in the management of hematologic neoplasms with germline predisposition: guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gachard N; Lafage-Pochitaloff M; Quessada J; Auger N; Collonge-Rame MA
Curr Res Transl Med; 2023; 71(4):103416. PubMed ID: 37865978
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Nguyen-Khac F; Daudignon A; Eclache V; Lafage-Pochitaloff M; Lefebvre C; Luquet I; Penther D
Ann Biol Clin (Paris); 2016 Oct; 74(5):509-510. PubMed ID: 27465598
[TBL] [Abstract][Full Text] [Related]
12. Guiding the global evolution of cytogenetic testing for hematologic malignancies.
Akkari YMN; Baughn LB; Dubuc AM; Smith AC; Mallo M; Dal Cin P; Diez Campelo M; Gallego MS; Granada Font I; Haase DT; Schlegelberger B; Slavutsky I; Mecucci C; Levine RL; Hasserjian RP; Solé F; Levy B; Xu X
Blood; 2022 Apr; 139(15):2273-2284. PubMed ID: 35167654
[TBL] [Abstract][Full Text] [Related]
13. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Jakobsen NA; Vyas P
Clin Med (Lond); 2018 Apr; 18(Suppl 2):s47-s53. PubMed ID: 29700093
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytogenetic and molecular cytogenetic studies on hematologic malignancies.
Kolialexi A; Tsangaris GT; Kitsiou S; Kanavakis E; Mavrou A
Anticancer Res; 2005; 25(4):2979-83. PubMed ID: 16080555
[TBL] [Abstract][Full Text] [Related]
15. [Molecular pathology: intersection of morphology, biochemistry and genetics].
Bosman FT
Ned Tijdschr Geneeskd; 1999 Nov; 143(45):2269-75. PubMed ID: 10578428
[TBL] [Abstract][Full Text] [Related]
16. [Novel diagnostic procedures for hematologic malignancies on the basis of genomic alterations].
Taniwaki M
Rinsho Ketsueki; 2001 May; 42(5):352-5. PubMed ID: 11452449
[No Abstract] [Full Text] [Related]
17. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.
Atluri H; Gerstein YS; DiNardo CD
Curr Hematol Malig Rep; 2022 Dec; 17(6):275-285. PubMed ID: 36279069
[TBL] [Abstract][Full Text] [Related]
18. Advances in next-generation sequencing and emerging technologies for hematologic malignancies.
Kwon R; Yeung CCS
Haematologica; 2024 Feb; 109(2):379-387. PubMed ID: 37584286
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnostics.
Braziel RM; Shipp MA; Feldman AL; Espina V; Winters M; Jaffe ES; Petricoin EF; Liotta LA
Hematology Am Soc Hematol Educ Program; 2003; ():279-93. PubMed ID: 14633786
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.
Epstein-Peterson ZD; Devlin SM; Stein EM; Klimek VM; Saltz LB; Tallman MS
Leuk Res; 2019 Jul; 82():19-23. PubMed ID: 31151028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
